Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Autor:	S. Spangenthal, G. Mizutani, Michelle Henley, D. Cheung, R.K. Zeldin, C. Vogelmeier, S.Z. Güçlü, J.B. Galdiz, C. Verkindre, Tim Overend
Rok vydání:	2009
Předmět:	Pulmonary and Respiratory Medicine Male Vital capacity medicine.drug_class Muscarinic Antagonists Ipratropium bromide Placebo Drug Administration Schedule FEV1/FVC ratio Pulmonary Disease Chronic Obstructive Double-Blind Method Bronchodilator Administration Inhalation Medicine Humans Pharmacology (medical) Aged Aged 80 and over business.industry Nebulizers and Vaporizers Biochemistry (medical) Area under the curve Middle Aged Glycopyrrolate Dry-powder inhaler Bronchodilator Agents Tolerability Anesthesia Female business medicine.drug
Zdroj:	Pulmonary pharmacologytherapeutics. 23(5)
ISSN:	1522-9629
Popis:	NVA237 is a novel once-daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and bronchodilator efficacy of two doses of NVA237 (100 and 200 microg), versus placebo, in patients with moderate-to-severe COPD (forced expiratory volume in 1s [FEV(1)]>or=30% and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ebc083fbea0fcf068f2a60825837808 https://pubmed.ncbi.nlm.nih.gov/20416390 Zobrazit plný text záznamu Full Text from ScienceDirect